Cell therapy is a procedure where living and intact cells are injected, implanted, or grafted into the patient's body. This technology relies on replacing dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, because of their ability to differentiate into the specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy also has applications in the development of regenerative medicines.
The Middle East and Africa cell therapy market is expected to reach US$ 346.7 million by 2027 from US$ 234.4 million in 2019; it is anticipated to grow at a CAGR of 5.1% during 2019–2027. Factors such as increasing prevalence of chronic diseases, rising adoption of regenerative medicines and increasing number of approvals for cell-based therapies are expected to boost the growth of the cell therapy market in the coming years. However, the market is likely to get impacted by the risk factor such as high cost of cell therapy manufacturing, during the forecast period.
COVID-19 pandemic has become the most significant challenge across the Middle East and Africa region. Countries such as UAE, and Saudi Arabia have also registered a significant number of positive patients. Therefore, countries have faced several challenges for their requirements. Initial phase of lockdown in various countries has affected the supply of many instruments in these regions. Therefore, many organizations are collaborating with others to overcome this pandemic by using cell therapies for the treatment of COVID 19. For instance, United Arab Emirates-based Abu Dhabi Stem Cells Center (ADSCC) has entered into collaboration agreement with Pluristem Therapeutics Inc. to develop cell therapies and regenerative medicines for the treatment of COVID-19.
The scope of the Middle East and Africa cell therapy market includes therapy type, product, technology, applications, end user and countries. In terms of therapy type, the allogeneic segment accounted for the largest share of the Middle East and Africa cell therapy market in 2019. In terms of product, the consumables segment accounted for the largest share of the Middle East and Africa cell therapy market in 2019. The viral vector technology segment accounted for the largest share of the Middle East and Africa cell therapy market, by technology, in 2019. In terms of applications, the Oncology segment accounted for the largest share of the Middle East and Africa cell therapy market in 2019. In terms of end user, the Research Institutes segment accounted for the largest share of the Middle East and Africa cell therapy market in 2019.
Several major primary and secondary sources associated with the Middle East and Africa cell therapy market report are the World Health Organization (WHO), Centers of Disease Control and Prevention (CDC), National Institute of Health of South Africa, and Department of Health Abu Dhabi, Abu Dhabi Stem Cell Center (ADSCC) and among others.
The Middle East and Africa Cell Therapy Market is valued at US$ 234.4 Million in 2019, it is projected to reach US$ 346.7 Million by 2027.
As per our report Middle East and Africa Cell Therapy Market, the market size is valued at US$ 234.4 Million in 2019, projecting it to reach US$ 346.7 Million by 2027. This translates to a CAGR of approximately 5.1% during the forecast period.
The Middle East and Africa Cell Therapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Cell Therapy Market report:
The Middle East and Africa Cell Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Cell Therapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Cell Therapy Market value chain can benefit from the information contained in a comprehensive market report.